SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Weight Loss: Advances in Hormone-Based Obesity Treatments
Advances in Hormone-Based Pharmacotherapies for Obesity
Hormone-based obesity treatments are improving the approach to weight management by targeting the body's neurometabolic systems. A recent
Beta-Blockers in Heart Attack Recovery: Reevaluating Their Role Based on Recent Research Insights
Beta-Blockers Heart Attack Research: Key Findings from Recent Meta-Analysis
Have you wondered if beta-blockers truly benefit heart attack survivors with normal heart function? Beta-blockers heart attack rese...
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Reductions
CTX310 Breakthrough in Lipid Disorder Treatment
CTX310 is a significant advancement as the first-in-human Phase 1 trial of this CRISPR-Cas9 gene-editing therapy...